{
    "clinical_study": {
        "@rank": "23223", 
        "arm_group": {
            "arm_group_label": "pompe safety sub-registry", 
            "description": "patients are selected from those who are enrolled in the Pompe Registry, and will be followed for safety evaluation in this sub-registry"
        }, 
        "brief_summary": {
            "textblock": "To collect uniform and meaningful data on patients with Pompe disease who experience\n      anaphylaxis, severe allergic reactions, and/or signals of severe cutaneous and/or systemic\n      immune complex-mediated reactions following treatment with alglucosidase alfa."
        }, 
        "brief_title": "Alglucosidase Alfa Pompe Safety Sub-Registry", 
        "completion_date": {
            "#text": "September 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Pompe Disease", 
        "condition_browse": {
            "mesh_term": [
                "Anaphylaxis", 
                "Glycogen Storage Disease Type II"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  the patient must be enrolled in the Pompe Registry;\n\n          -  have a confirmed diagnosis of Pompe disease (confirmation of diagnosis is defined as\n             documented GAA enzyme deficiency from any tissue source and/or documentation of 2 GAA\n             gene mutations);\n\n          -  be na\u00efve to treatment with alglucosidase alfa (4000-L), plan to be treated with\n             alglucosidase alfa, or have been treated with alglucosidase alfa for less than 2\n             years.\n\n        Exclusion Criteria:\n\n          -  if the patient does not plan to receive treatment with alglucosidase alfa (4000-L\n             scale)\n\n          -  patients who have received an investigational drug (excluding alglucosidase alfa)\n             within 30 days prior to signing a sub-registry consent form\n\n          -  if they are taking or plan to take any investigational product while enrolled in the\n             sub-registry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients who enrolled in the Pompe Registry will be enrolled in this sub-registry. include\n        patients with infantile-onset Pompe disease, as well as those with late-onset Pompe\n        disease.\n\n        An approximately equal proportion of currently treated and treatment-na\u00efve patients is\n        targeted for enrollment at each site."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710813", 
            "org_study_id": "AGLU06909", 
            "secondary_id": "LTS13930"
        }, 
        "intervention": {
            "arm_group_label": "pompe safety sub-registry", 
            "description": "IV infusion of 20 mg/kg; qow", 
            "intervention_name": "Alglucosidase alfa", 
            "intervention_type": "Biological", 
            "other_name": "Myozyme; Lumizyme"
        }, 
        "intervention_browse": {
            "mesh_term": "Antigen-Antibody Complex"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "pompe disease", 
            "alglucosidase alfa", 
            "anaphylaxis", 
            "severe cutaneous", 
            "systemic immune complex-mediated reactions"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cambridge", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune Complex Mediated Reactions With Alglucosidase Alfa Treatment", 
        "overall_contact": {
            "email": "medinfo@genzyme.com", 
            "last_name": "Medical Information", 
            "phone": "8007454447"
        }, 
        "overall_contact_backup": {
            "email": "medinfo@genzyme.com", 
            "last_name": "Medical Information", 
            "phone": "6172527832"
        }, 
        "overall_official": {
            "affiliation": "Genzyme, a Sanofi Company", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "collect meaningful data on patients with these outcomes following treatment with alglucosidase alfa manufactured at the 4000-L scale", 
            "measure": "number of patients experience anaphylaxis, severe allergic reactions and/or signals of severe cutaneous and/or systematic immune complex-mediated reactions", 
            "safety_issue": "No", 
            "time_frame": "4 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710813"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}